https://orcid.org/0000-0002-3131-3718
References
- Cruz LCHd, Rodriguez I, Domingues RC, et al. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol. 2011;32(11):1978–1985.
- Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced Squamous-Cell Non-Small-Cell lung cancer. N Engl J Med. 2015;373(2):123–135.
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
- Hodi FS, Sznol M, Kluger HM, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol. 2014;32(15_suppl):9002–9002.
- Chanan-Khan A, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. 2011.
- Ferrajoli A, Lee B-N, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111(11):5291–5297.
- Eve HE, Rule SAJ. Lenalidomide-induced tumour flare reaction in mantle cell lymphoma. Br J Haematol. 2010;151(4):410–412.
- Kayar Y, Kayar NB. Tumor flare reaction in a patient with mantle cell lymphoma. Blood Res. 2014;49(4):279–280.
- Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in waldenstrom’s macroglobulinemia. Ann Oncol. 2004;15(10):1481–1483.
- Ghobrial IM, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group, et al. Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with waldenstrom macroglobulinemia: an Eastern cooperative oncology group study. Cancer. 2004;101(11):2593–2598.
- Cheson BD, Ansell S, Schwartz L, et al. Refinement of the lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489–2496.
- Wang J, Hu Y, Yang S, et al. Role of fluorodeoxyglucose positron emission tomography/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with Non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25(6):1092–1098.
- Danylesko I, Shouval R, Shem-Tov N, et al. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplant. 2021;56(5):1134–1143.
- Boursier C, Perrin M, Bordonne M, et al. Early 18F-FDG PET flare-up phenomenon after CAR T-Cell therapy in lymphoma. Clin Nucl Med. 2022;47(2):e152–e153.
- Jin A, Feng J, Wang Z, et al. Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2019;54(7):969–972.
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638.
- Cheson BD, Fisher RI, Barrington SF, United Kingdom National Cancer Research Institute, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and Non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
- Taleb BA. Tumour flare reaction in cancer treatments: a comprehensive literature review. Anticancer Drugs. 2019;30(9):953–958.